KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Capital Expenditures (2016 - 2025)

Pacific Biosciences Of California has reported Capital Expenditures over the past 16 years, most recently at $861000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $861000.0 for Q4 2025, down 46.75% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (down 56.14% YoY), and the annual figure for FY2025 was $2.7 million, down 56.14%.
  • Capital Expenditures for Q4 2025 was $861000.0 at Pacific Biosciences Of California, up from -$86000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for PACB hit a ceiling of $4.9 million in Q4 2022 and a floor of -$787000.0 in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $1.6 million (2024), compared with a mean of $2.1 million.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 4141.79% in 2021 and later crashed 194.82% in 2024.
  • Pacific Biosciences Of California's Capital Expenditures stood at $2.8 million in 2021, then skyrocketed by 72.55% to $4.9 million in 2022, then crashed by 58.73% to $2.0 million in 2023, then fell by 20.11% to $1.6 million in 2024, then crashed by 46.75% to $861000.0 in 2025.
  • The last three reported values for Capital Expenditures were $861000.0 (Q4 2025), -$86000.0 (Q3 2025), and $550000.0 (Q2 2025) per Business Quant data.